Authors: Carrieri, P Cailleton, V Le Moing, V Spire, B Dellamonica, P Bouvet, E Raffi, F Journot, V Moatti, JP

Citation: P. Carrieri et al., The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO cohort, J ACQ IMM D, 28(3), 2001, pp. 232-239

Authors: Binquet, C Chene, G Jacqmin-Gadda, H Journot, V Saves, M Lacoste, D Dabis, F

Citation: C. Binquet et al., Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections - The Aquitaine Cohort, 1996-1997, AM J EPIDEM, 153(4), 2001, pp. 386-393

Authors: Molina, JM Ferchal, F Rancinan, C Raffi, F Rozenbaum, W Sereni, D Morlat, P Journot, V Decazes, JM Chene, G

Citation: Jm. Molina et al., Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients, J INFEC DIS, 182(2), 2000, pp. 599-602

Authors: Molina, JM Cheuc, G Ferchal, F Journot, V Pellegrin, I Sombardier, MN Rancinan, C Cotte, L Madelaine, I Debord, T Decazes, JM

Citation: Jm. Molina et al., Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients, ANTIVIR TH, 4, 1999, pp. 71-74

Authors: Molina, JM Chene, G Ferchal, F Journot, V Pellegrin, I Sombardier, MN Rancinan, C Cotte, L Madelaine, I Debord, T Decazes, JM

Citation: Jm. Molina et al., The ALBI trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus, J INFEC DIS, 180(2), 1999, pp. 351-358